[Pyr 1 ]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart
- 1 September 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 54 (3), 598-604
- https://doi.org/10.1161/hypertensionaha.109.134619
Abstract
Apelin receptors, present on vascular smooth muscle cells, endothelium, and cardiomyocytes, are activated by the family of apelin peptides to elicit cardiovascular effects in experimental animals, but functional activity in humans has not been studied in detail. We detected low levels of apelin immunoreactivity in plasma of volunteers consistent with an autocrine/paracrine action and detected apelin immunoreactivity in the supernatant from human cultured endothelial cells. We found that [Pyr 1 ]apelin-13 was the predominant isoform in cardiac tissue from patients with coronary artery disease. We tested the hypothesis that apelins have vascular and cardiac actions in human tissues in vitro and compared responses to [Pyr 1 ]apelin-13, apelin-13, and apelin-36. In endothelium-intact mammary artery, all 3 of the apelins induced concentration-dependent vasodilatation with comparable potency (EC 50 : 0.6 to 1.6 nM; maximum response: 40% to 50%). Vasodilatation was abolished after endothelial removal or preincubation with indomethacin but was unaffected by preincubation with N G -nitro- l -arginine methyl ester, indicating involvement of prostanoids but not NO in dilatation by apelins in this patient group. Apelins were potent constrictors of endothelium-denuded saphenous vein (EC 50 : 0.6 to 1.6 nM; maximum response: 17% to 26%) and mammary artery ([Pyr 1 ]apelin-13; EC 50 : 0.2 nM; maximum response: 29%). In paced atrial strips, all 3 of the peptides increased the force of contraction with subnanomolar potencies (EC 50 : 40 to 125 pM). For the first time, we demonstrate that the 3 principal forms of apelin have comparable potency and efficacy in human cardiovascular tissues. Apelins are potent endothelium-dependent vasodilators acting via a prostanoid-dependent mechanism; however, removal of the endothelium revealed direct vasoconstrictor actions in both the artery and vein. Furthermore, in human cardiac tissue, the apelin peptides are among the most potent endogenous positive inotropic agents yet reported.Keywords
This publication has 42 references indexed in Scilit:
- Impaired Heart Contractility in Apelin Gene–Deficient Mice Associated With Aging and Pressure OverloadCirculation Research, 2007
- Direct effects of apelin on cardiomyocyte contractility and electrophysiologyBiochemical and Biophysical Research Communications, 2007
- Apelin increases contractility in failing cardiac muscleEuropean Journal of Pharmacology, 2006
- Apelin Stimulates Myosin Light Chain Phosphorylation in Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Behavioral, neuroendocrine and thermoregulatory actions of apelin-13Neuroscience, 2004
- Apelin (65‐77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cellsThe FASEB Journal, 2004
- Apelin Has In Vivo Inotropic Effects on Normal and Failing HeartsCirculation, 2004
- Regulatory Roles for APJ, a Seven-transmembrane Receptor Related to Angiotensin-type 1 Receptor in Blood Pressure in VivoOnline Journal of Public Health Informatics, 2004
- Molecular and Functional Characteristics of APJOnline Journal of Public Health Informatics, 2000
- Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ ReceptorBiochemical and Biophysical Research Communications, 1998